Page last updated: 2024-12-08

okadaic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID57059112
CHEBI ID131162
MeSH IDM0028765
PubMed CID446512
CHEMBL ID280487
CHEMBL ID158524
CHEBI ID44658
SCHEMBL ID131485
MeSH IDM0028765

Synonyms (38)

Synonym
78111-17-8
okadaic acid
CHEBI:131162
c44h68o13
OKA ,
PROBES1_000180
okadaic acid from prorocentrum concavum, >=90% (hplc), translucent film
okadaic acid from prorocentrum concavum, 92-100% (hplc)
CHEBI:44658 ,
1U32
DB02169
bdbm50110676
chembl280487 ,
chembl158524
bdbm50097634
okadaic acid from prorocentrum concavum
1JK7
gtpl5349
(2r)-3-[(2s,5r,6r,8s)-8-[(2r,3e)-4-[(2r,4'ar,5r,6's,8'r,8'as)-8'-hydroxy-6'-[(1s,3s)-1-hydroxy-3-[(2s,3r,6s)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-7'-methylidene-hexahydro-3'h-spiro[oxolane-2,2'-pyrano[3,2-b]pyran]-5-yl]but-3-en-2-yl]-5-hydroxy-
SCHEMBL131485
(.alpha.r,2s,5r,6r,8s)-.alpha.,5-dihydroxy-.alpha.,10-dimethyl-8-((1r,2e)-1-methyl-3-((2r,4'ar,5r,6's,8'r,8'as)-octahydro-8'-hydroxy-6'-((1s,3s)-1-hydroxy-3-((2s,3r,6s)-3-methyl-1,7-dioxaspiro(5.5)undec-2-yl)butyl)-7'-methylenespiro(furan-2(3h),2'(3'h)-py
okadaic acid [hsdb]
(2r)-3-((2s,6r,8s,11r)-2-((e,2r)-4-((2s,2'r,4r,4as,6r,8ar)-4-hydroxy-2-((1s,3s)-1-hydroxy-3-((2s,3r,6s)-3-methyl-1,7-dioxaspiro(5.5)undecan-2-yl)butyl)-3-methylidenespiro(4a,7,8,8a-tetrahydro-4h-pyrano(3,2-b)pyran-6,5'-oxolane)-2'-yl)but-3-en-2-yl)-11-hyd
35-demethyldinophysistoxin 1
okadaic acid [mi]
35-demethyl-dtx 1
1,7-dioxaspiro(5.5)undec-10-ene-2-propanoic acid, .alpha.,5-dihydroxy-.alpha.,10-dimethyl-8-((1r,2e)-1-methyl-3-((2r,4'ar,5r,6's,8'r,8'as)-octahydro-8'-hydroxy-6'-((1s,3s)-1-hydroxy-3-((2s,3r,6s)-3-methyl-1,7-dioxaspiro(5.5)undec-2-yl)butyl)-7'-methylenes
HB0468
(2r)-2-hydroxy-3-[(2s,5r,6r,8s)-5-hydroxy-8-{(1r,2e)-3-[(2r,4a'r,5r,6's,8'r,8a's)-8'-hydroxy-6'-{(1s,3s)-1-hydroxy-3-[(2s,3r,6s)-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]butyl}-7'-methylideneoctahydro-3h,3'h-spiro[furan-2,2'-pyrano[3,2-b]pyran]-5-yl]-1-meth
(2r)-3-[(2s,5r,6r,8s)-8-{(2r,3e)-4-[(2r,4'ar,5r,6's,8'r,8'as)-8'-hydroxy-6'-{(1s,3s)-1-hydroxy-3-[(2s,3r,6s)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl}-7'-methylidenehexahydro-3'h-spiro[oxolane-2,2'-pyrano[3,2-b]pyran]-5-yl]but-3-en-2-yl}-5-hydroxy-1
DTXSID60880002
Q414042
CS-0014219
oa and nsc 677083
HY-N6785
AT32065
1,7-dioxaspiro[5.5]undec-10-ene-2-propanoic acid, .alpha,5-dihydroxy-.alpha.,10-dimethyl-8-[(1r,2e)-1-methyl-3-[(2r,4'ar,5r,6's,8'r,8'as)-octahydro-8'-hydroxy-6'-[(1s,3s)-1-hydroxy-3-[(2s,3r,6s)-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]butyl]-7'-methylenesp
AKOS040742329

Research Excerpts

Overview

Okadaic acid is a potent inhibitor of select serine/threonine protein phosphatases. It is an extremely useful tool for studying processes that are regulated by phosphorylation.

ExcerptReferenceRelevance
"Okadaic acid is a potent inhibitor of select serine/threonine protein phosphatases. "( Importance of the C28-C38 hydrophobic domain of okadaic acid for potent inhibition of protein serine-threonine phosphatases 1 and 2A.
Dounay, AB; Forsyth, CJ; Frydrychowski, VA; Urbanek, RA, 2001
)
2.01
"Okadaic acid (OA) is a toxin responsible for diarrhetic shellfish poisoning and is an extremely useful tool for studying processes that are regulated by phosphorylation, although the exact mechanism of action is still undetermined. "( Self-association of okadaic acid upon complexation with potassium ion.
Daranas, AH; Fernández, JJ; Gavín, JA; Morales, EQ; Norte, M, 2004
)
2.09

Toxicity

Prorocentrum lima is a dinoflagellate that forms hazardous blooms and produces okadaic acid. The presence of toxic metals ions such as Chromium (Cr) and Cadmium (Cd) in meat, shells, and water released by the clams prompted us to experiment in Caco-2 intestinal cell line.

ExcerptReferenceRelevance
"Microcystins and nodularin, isolated from toxic blue-green algae, are hepatotoxic monocyclic polypeptides."( Inhibition of protein phosphatases by microcystins and nodularin associated with hepatotoxicity.
Carmichael, WW; Fujiki, H; Harada, K; Ichihara, A; Matsushima, R; Watanabe, MF; Yoshizawa, S, 1990
)
0.28
" The 100% CHC1(3) eluate proved to be the most toxic (mouse killed in 32 minutes) and the 10% MeOH-CHC1(3) fraction killed in approximately 48 hours."( Characterization of marine toxin(s) in Myripristis sp. by immunological, mouse toxicity, and guinea pig assays.
Asahina, AY; Ganal, CA; Hokama, Y; Miyahara, JT, 1993
)
0.29
" OA diol-ester was found to be nearly as toxic as OA."( Comparative toxicity of the diarrhetic shellfish poisons, okadaic acid, okadaic acid diol-ester and dinophysistoxin-4, to the diatom Thalassiosira weissflogii.
McLachlan, JL; Quilliam, MA; Windust, AJ; Wright, JL, 1997
)
0.3
" All samples had previously been found to be highly toxic in mice, with symptoms indicating the presence of non-diarrheagenic toxins in the mouse bioassay."( Oral toxicity in mice of algal toxins from the diarrheic shellfish toxin (DST) complex and associated toxins.
Aune, T; Nordstoga, K; Stabell, OB; Tjøtta, K, 1998
)
0.3
" OA induced the already known toxic signs: before death, mice were motionless and cyanotic; small intestine and liver damage were shown at post-mortem."( Oral and intraperitoneal acute toxicity studies of yessotoxin and homoyessotoxins in mice.
Altinier, G; Carbonatto, M; Melato, M; Satake, M; Sosa, S; Tubaro, A; Vita, F; Yasumoto, T, 2003
)
0.32
" Necroscopy and/or light microscopy analysis revealed toxic effects mainly at forestomach (ulceration and hyperplasia), liver and, indirectly to body weight loss of mice, atrophic signs in the lymphoid organs and exocrine pancreas."( Short-term oral toxicity of homoyessotoxins, yessotoxin and okadaic acid in mice.
Altinier, G; Della Loggia, R; Satake, M; Soranzo, MR; Sosa, S; Tubaro, A; Yasumoto, T, 2004
)
0.32
" Its occurrence in food web and mollusks reaction on toxic algae presence in water are described."( [Biosafety: phicotoxins (part 3)].
Khotimchenko, SA; Kokhanova, IuA, 2006
)
0.33
" In accordance with the response surface design model, the LD50 for DTX-2 and OA was 338 and 206 microg/kg, respectively."( Relative toxicity of dinophysistoxin-2 (DTX-2) compared with okadaic acid, based on acute intraperitoneal toxicity in mice.
Aasen, JA; Aune, T; Hess, P; Larsen, S; Rehmann, N; Satake, M, 2007
)
0.34
" Sample extracts (crude extracts, CE) were obtained from algal cultures and their toxic potential was explored."( Toxicity to medaka fish embryo development of okadaic acid and crude extracts of Prorocentrum dinoflagellates.
Chateau-Joubert, S; Crespeau, F; Edery, M; Escoffier, N; Gaudin, J; Huet, H; Mezhoud, K; Turquet, J, 2007
)
0.34
" The presence of toxic metals ions such as Chromium (Cr) and Cadmium (Cd) in meat, shells, and water released by the clams prompted us to experiment in Caco-2 intestinal cell line toxic effects of these heavy metals ions in combination with okadaic acid, one DSP present in clams to assess the potential global toxicity."( Combined cytotoxicity and genotoxicity of a marine toxin and seafood contaminant metal ions (chromium and cadmium).
Creppy, EE; Maaroufi, K; Moukha, S; Souid-Mensi, G, 2008
)
0.35
" Recent studies indicate that DTX-2 is about half as toxic and has about half the affinity for protein phosphatase 2A (PP2A) as OA."( A structural basis for the reduced toxicity of dinophysistoxin-2.
Arcus, V; Cox, NR; Huhn, J; Jeffrey, PD; Larsen, K; Miles, CO; Rise, F; Rundberget, T; Shi, Y, 2009
)
0.35
" In humans, consumption of OA induces acute toxic effects like diarrhoea, nausea, vomiting and abdominal pain."( Embryotoxic effects of the marine biotoxin okadaic acid on murine embryonic stem cells.
Al-Hamwi, R; Ehlers, A; Lampen, A; Stempin, S, 2010
)
0.36
" Toxic manifestations occur all year round at a higher or lesser intensity, and as a consequence, extractive production factories need to be closed during these periods which affects the economy of aquaculture industries."( Evaluation of genotoxicity in gills and hemolymph of clam Ruditapes decussatus fed with the toxic dinoflagellate Prorocentrum lima.
Fernández-Tajes, J; Flórez-Barrós, F; Méndez, J; Prado-Alvarez, M, 2011
)
0.37
" It is now repeatedly stated in the literature that protein phosphatase inhibition is not only responsible for the intestinal effects of OA and derivatives, but also for their acute toxic effects, their tumour promoting activity and their neuronal toxicity."( Is protein phosphatase inhibition responsible for the toxic effects of okadaic Acid in animals?
Munday, R, 2013
)
0.39
" With this in mind, the present work aimed to provide a timely and comprehensive insight into the current literature on the effect of OA in marine invertebrates, along with the strategies developed by these organisms to respond to its toxic effect together with the most important methods and techniques used for OA detection and evaluation."( Okadaic acid meet and greet: an insight into detection methods, response strategies and genotoxic effects in marine invertebrates.
Eirín-López, JM; Méndez, J; Prego-Faraldo, MV; Valdiglesias, V, 2013
)
0.39
" Seafood contamination by these compounds, also at low concentrations and for a long period of time, can increase the possibility of their simultaneous and repeated ingestion, with possible synergistic toxic effects."( Repeated oral co-exposure to yessotoxin and okadaic acid: a short term toxicity study in mice.
Ardizzone, M; Barreras, A; Beltramo, D; Dell'Ovo, V; Sosa, S; Tubaro, A; Vita, F; Yasumoto, T, 2013
)
0.39
" Studies carried out in mice indicated that DSP poisonous are toxic towards experimental animals with a lethal oral dose 2-10 times higher than the intraperitoneal (i."( Experimental basis for the high oral toxicity of dinophysistoxin 1: a comparative study of DSP.
Botana, LM; Fernández, DA; Fraga, M; Louzao, MC; Vieytes, MR; Vilariño, N, 2014
)
0.4
" Consumption of contaminated shellfish induces acute toxic effects such as diarrhea, nausea, vomiting, and abdominal pain."( CYP3A4 activity reduces the cytotoxic effects of okadaic acid in HepaRG cells.
Fessard, V; Hurtaud-Pessel, D; Kittler, K; Maul, R, 2014
)
0.4
" DTX-1 displayed the most toxic effect in the three tested cell lines."( Evaluation of okadaic acid, dinophysistoxin-1 and dinophysistoxin-2 toxicity on Neuro-2a, NG108-15 and MCF-7 cell lines.
Diogène, J; Soliño, L; Sureda, FX, 2015
)
0.42
" Moreover, we found that inhibition of CYP3A4 activity by ketoconazole enhances the toxic effects of OA, DTX-1, DTX-2, and PTX-2 in HepaRG cells."( Modulation of CYP3A4 activity alters the cytotoxicity of lipophilic phycotoxins in human hepatic HepaRG cells.
De Sousa, G; Dubreil, E; Ferron, PJ; Fessard, V; Hogeveen, K; Le Hegarat, L; Rahmani, R, 2016
)
0.43
" The obtained results revealed that in vivo exposure to this toxic microalgae induced early genotoxicity in hemocytes, as a consequence of oxidative DNA damage."( Early Genotoxic and Cytotoxic Effects of the Toxic Dinoflagellate Prorocentrum lima in the Mussel Mytilus galloprovincialis.
Eirin-Lopez, JM; Laffon, B; Mendez, J; Prego-Faraldo, MV; Valdiglesias, V, 2016
)
0.43
"Exposure to chemicals might be toxic to the developing brain."( Comparison of neurons derived from mouse P19, rat PC12 and human SH-SY5Y cells in the assessment of chemical- and toxin-induced neurotoxicity.
Jacobsson, SOP; Karlsson, J; Popova, D, 2017
)
0.46
" Thus, it may be considered that toxicity potential of DTX-1 has remained underestimated as compared to that of OA and DTX-1 might be more toxic than OA."( Comparative toxicity of dinophysistoxin-1 and okadaic acid in mice.
Okada, Y; Suzuki, H, 2018
)
0.48
" They had different toxicokinetics and toxic potency."( Toxic Action Reevaluation of Okadaic Acid, Dinophysistoxin-1 and Dinophysistoxin-2: Toxicity Equivalency Factors Based on the Oral Toxicity Study.
Abal, P; Botana, AM; Botana, LM; Carrera, C; Louzao, MC; Suzuki, T; Vieytes, MR; Vilariño, N; Watanabe, R, 2018
)
0.48
" Results confirmed that DTX1 is more toxic than OA by oral route while DTX2 is less toxic."( Toxic Action Reevaluation of Okadaic Acid, Dinophysistoxin-1 and Dinophysistoxin-2: Toxicity Equivalency Factors Based on the Oral Toxicity Study.
Abal, P; Botana, AM; Botana, LM; Carrera, C; Louzao, MC; Suzuki, T; Vieytes, MR; Vilariño, N; Watanabe, R, 2018
)
0.48
" However, recent in vitro studies indicated that DTX-1 seems to be more toxic than OA."( Benchmark dose analyses of γH2AX and pH3 endpoints for quantitative comparison of in vitro genotoxicity potential of lipophilic phycotoxins.
Fessard, V; Le Hegarat, L; Roudot, AC, 2020
)
0.56
"Prorocentrum lima is a dinoflagellate that forms hazardous blooms and produces okadaic acid (OA), leading to adverse environmental consequences associated with the declines of zooplankton populations."( Molecular mechanisms of zooplanktonic toxicity in the okadaic acid-producing dinoflagellate Prorocentrum lima.
Challis, JK; Codling, G; Geng, N; Giesy, JP; Gong, Y; Liu, R; Wu, M; Xu, EG; Yi, X; Zhang, K, 2021
)
0.62
"The frequent occurrence of marine dinoflagellates producing palytoxin (PLTX) or okadaic acid (OA) raises concern for the possible co-presence of these toxins in seafood, leading to additive or synergistic adverse effects in consumers."( Acute Toxicity by Oral Co-Exposure to Palytoxin and Okadaic Acid in Mice.
Carlin, M; Pelin, M; Ponti, C; Sosa, S; Tubaro, A, 2022
)
0.72

Compound-Compound Interactions

Oocyte maturation and subsequent embryo development in the presence of nicotine in combination with okadaic acid and taxol.

ExcerptReferenceRelevance
" These results suggest that the signal transduction mechanisms regulating induction of acute-phase proteins by IL-6, either alone or in combination with IL-1, are mediated by activation of protein phosphatases 1 and/or 2A."( Okadaic acid, an inhibitor of protein phosphatases 1 and 2A, inhibits induction of acute-phase proteins by interleukin-6 alone or in combination with interleukin-1 in human hepatoma cell lines.
Ganapathi, MK, 1992
)
0.28
" Then, in order to discriminate between a clastogenic or aneugenic effect of OA, the micronucleus assay was carried out in combination with fluorescence in situ hybridization (FISH) using a (TTAGGG)(n) DNA probe for centromere detection."( Aneugenic potential of okadaic acid revealed by the micronucleus assay combined with the FISH technique in CHO-K1 cells.
Dragacci, S; Fessard, V; Le Hegarat, L; Poul, JM; Puech, L, 2003
)
0.32
"To investigate the effects of nicotine in combination with okadaic acid (OA) or taxol on bovine oocyte maturation and subsequent embryonic development."( Nicotine combined with okadaic acid or taxol adversely affects bovine oocyte maturation and subsequent embryo development.
Bunch, TD; Li, GP; Liu, Y; Sessions, BR; White, KL; Yang, S, 2009
)
0.35
"Oocyte maturation and subsequent embryo development in the presence of nicotine in combination with okadaic acid and taxol."( Nicotine combined with okadaic acid or taxol adversely affects bovine oocyte maturation and subsequent embryo development.
Bunch, TD; Li, GP; Liu, Y; Sessions, BR; White, KL; Yang, S, 2009
)
0.35
"05 micromol/L) did not affect oocyte haploid composition; however, taxol alone or combined with nicotine caused a decrease in haploid composition compared with control."( Nicotine combined with okadaic acid or taxol adversely affects bovine oocyte maturation and subsequent embryo development.
Bunch, TD; Li, GP; Liu, Y; Sessions, BR; White, KL; Yang, S, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
"An orally bioavailable and blood-brain barrier penetrating analog of the kinase inhibitor K252a was able to prevent the typical motor deficits in the tau (P301L) transgenic mouse model (JNPL3) and markedly reduce soluble aggregated hyperphosphorylated tau."( An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice.
Dickson, DW; Eriksen, J; Hübinger, G; Hutton, M; Klafki, HW; Le Corre, S; Lewis, J; McGowan, E; Monse, B; Obermeier, A; Plesnila, N; Roder, HM; Sahagún, H; Seneci, P; Yue, M; Zehr, C, 2006
)
0.33
" NNZ-2566 is a structural analogue of Glypromate, resulting from alpha-methylation of the proline moiety, which has improved the elimination half-life and oral bioavailability over the parent peptide."( NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke.
Batchelor, DC; Bickerdike, MJ; Brimble, MA; Gluckman, PD; Harris, PW; Leong, W; Lin, H; Sieg, F; Sirimanne, ES; Thomas, GB; Wen, J, 2009
)
0.35
" Therefore, our in vitro data indicate that humans appear to have efficient defense mechanisms to protect themselves against low-dose contaminated shellfish by exhibiting a low bioavailability as a result of active elimination of OA by P-gp."( Active elimination of the marine biotoxin okadaic acid by P-glycoprotein through an in vitro gastrointestinal barrier.
Ehlers, A; Hessel, S; Lampen, A; Preiss-Weigert, A; These, A, 2014
)
0.4

Dosage Studied

Okadaic acid inhibits type 1 protein phosphatase PP-2A. Dose-response studies showed a progressive increase in migration of non-metastatic LLC-C8 cells.

ExcerptRelevanceReference
" In rat pancreatic acini, 1 microM okadaic acid shifted the cholecystokinin (CCK) dose-response curve for stimulating amylase release to the right without reducing maximal secretion."( Effects of okadaic acid indicate a role for dephosphorylation in pancreatic stimulus-secretion coupling.
Wagner, AC; Williams, JA; Wishart, MJ; Yule, DI, 1992
)
0.28
" This was seen as a 5-6-fold right shift in the dose-response curves for AVP action (cAMP accumulation in intact cells and AC stimulation in homogenates and isolated membranes) and in a decrease in the maximum effect of AVP on these parameters."( Desensitization of the human V2 vasopressin receptor. Homologous effects in the absence of heterologous desensitization.
Antaramian, A; Birnbaumer, M; Gilbert, S; Themmen, AP, 1992
)
0.28
" Both samples revealed an exponential pattern in the dose-response relationship."( An evaluation of the mouse bioassay applied to extracts of 'diarrhoetic' shellfish toxins.
Aune, T; Stabell, OB; Steffenak, I, 1992
)
0.28
" The dose-response curve for okadaic acid suggests its action is on a type 1 protein phosphatase."( Okadaic acid inhibits activation of K-Cl cotransport in red blood cells containing hemoglobins S and C.
Brockenbrough, JS; Glosson, PS; Orringer, EP; Parker, JC; Whitney, JA, 1991
)
0.28
" Comparison of the dose-response curves of OA on maturation, isolated enzymes and phosphatase activities in crude oocyte preparations suggests that inhibition of both polycation-stimulated (PCS) and ATP,Mg-dependent (AMD) phosphatases is sufficient but requires that a critical phosphorylation level is attained of one or several of their substrates, resulting in the formation of active MPF and meiotic maturation."( Okadaic acid, a specific protein phosphatase inhibitor, induces maturation and MPF formation in Xenopus laevis oocytes.
Goris, J; Hendrix, P; Hermann, J; Merlevede, W; Ozon, R, 1989
)
0.28
" The ADR dose-response curve is significantly shifted to the right when cells were preincubated with the unspecific phosphodiesterase inhibitor IBMX."( Study of the activation mechanism of adriamycin on rat mast cells.
Botana, LM; Estévez, MD; Vieytes, MR, 1994
)
0.29
" The dose-response and the time-course of the inhibitor, however, indicated that the site of action of TPCK for NF-kappa B activation and for DNA fragmentation are quite distinct."( Protease inhibitors differentially regulate tumor necrosis factor-induced apoptosis, nuclear factor-kappa B activation, cytotoxicity, and differentiation.
Aggarwal, BB; Chan, H; Higuchi, M; Singh, S, 1995
)
0.29
" In no case did the mussel homogenate compromise the dose-response curve to okadaic acid when data were normalized to the appropriate control value."( Use of cultured permanent lines of intestinal epithelial cells for the assay of okadaic acid in mussel homogenates.
Blay, J; Poon, AS, 1995
)
0.29
" Similarly, phosphorylation of MAPK in tyrosine residues, as found in immunoblots using anti-phosphotyrosine antibodies, follows similar time- and dose-response curves as the kinase activation."( Direct stimulation by tyrosine phosphorylation of microtubule-associated protein (MAP) kinase activity by granulocyte-macrophage colony-stimulating factor in human neutrophils.
Colasanto, JM; Gomez-Cambronero, J; Huang, CK; Sha'afi, RI, 1993
)
0.29
" An alternative to the use of mice is the mosquito bioassay, which was recently used to obtain a dose-response relationship between ingested ciguatoxin and clinical symptoms in man."( Evolution of methods for assessing ciguatera toxins in fish.
Park, DL, 1994
)
0.29
" The dose-response of insulin effect shows a behavior typical of other insulin responses: a maximum in the physiological range (1 nM) and smaller effects at higher and lower hormone concentrations."( Modulation of the Na-H antiport by insulin: interplay between protein kinase C, tyrosine kinase, and protein phosphatases.
Baldini, P; Bellucci, V; Incerpi, S; Luly, P; Zannetti, A, 1994
)
0.29
" The dose-response curve shows a maximal effect at 25 nM OA (2."( Okadaic acid, a protein phosphatase inhibitor, enhances transcription of a receptor gene containing sequence A of the human prolactin promoter.
Belayew, A; Martial, JA; Wera, S, 1993
)
0.29
" Staurosporin potentiated Ca(2+)-induced Peth formation by shifting the [Ca2+]cyt dose-response curve to the left."( The role of cytosolic Ca2+, protein kinase C, and protein kinase A in hormonal stimulation of phospholipase D in rat hepatocytes.
Benistant, C; Gustavsson, L; Hoek, JB; Moehren, G; Rubin, R; Torres-Marquez, ME, 1994
)
0.29
" Namely, we find different dose-response relationships for the two kinetic effects of increased opening probability (mode 1) and prolongation of opening (mode 2)."( Two phosphatase sites on the Ca2+ channel affecting different kinetic functions.
Fozzard, HA; Ono, K, 1993
)
0.29
" Dose-response studies with concentrations of okadaic acid that selectively inhibited PP-2A or both PP-2A and PP-1 showed a progressive increase in migration of non-metastatic LLC-C8 cells, suggesting that both PP-1 and PP-2A limit their motility."( Protein phosphatases limit tumor motility.
Djorjevic, A; Lozano, Y; Maier, GD; Young, MR, 1993
)
0.29
" The dose-response curves obtained with different transmitters all shifted downward after the activation of PKC, but the ED50 of each transmitter remained unchanged."( Functional uncoupling between the receptor and G-protein as the result of PKC activation, observed in Aplysia neurons.
Fujita, R; Kawasaki, S; Kimura, S; Matsumoto, M; Sasaki, K; Sato, M; Takashima, K, 1997
)
0.3
" Dose-response curves to the hormone were determined in the absence and in the presence of several drugs that affect sequential steps of the Ca(2+)-dependent signalling pathway."( Cellular signalling of PCH-induced pigment aggregation in the crustacean Macrobrachium potiuna erythrophores.
Castrucci, AM; da Silva, MA; Josefsson, L; Nery, LE, 1997
)
0.3
" The dose-response relationship of the yield of prematurely condensed ring chromosomes (PCC rings) in the irradiated lymphocytes was examined."( Easy biodosimetry for high-dose radiation exposures using drug-induced, prematurely condensed chromosomes.
Hayata, I; Kanda, R; Lloyd, DC, 1999
)
0.3
"05) OA dose-response increases in the frequencies of metaphase I (MI) arrested oocytes, MI oocytes with 80 chromatids instead of the normal 20 tetrads, and anaphase I telophase I (AI-TI) oocytes with two groups of an unequal number of chromatids were found."( Okadaic acid, an inhibitor of protein phosphatase 1 and 2A, induces premature separation of sister chromatids during meiosis I and aneuploidy in mouse oocytes in vitro.
Fuseler, JW; Hilliard, C; London, SN; Mailhes, JB, 2003
)
0.32
"ATRA, okadaic acid (OKA) and ATRA + OKA at the same dosage were incubated with NB4 and MR2 cells respectively."( [Effect of okadaic acid on differentiation of NB4 and MR2 cells induced by all-trans retinoic acid].
Chen, JH; Ou-Yang, J; Xia, YQ; Xie, PH; Xu, XH, 2008
)
0.35
") enhanced the ascending (3 mgxkg(-1)) and descending (30 mgxkg(-1)) portions of buprenorphine's dose-response curve, but only spinal, not supraspinal, nociceptin (10 nmolxL(-1)) enhanced buprenorphine anti-nociception."( Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine.
Ding, Z; Raffa, RB, 2009
)
0.35
" PP2A assays were also carried out with predefined mixtures of OA and OOH, covering the full dose-response of one compound in the presence of increasing concentrations of the other toxin."( The total activity of a mixture of okadaic acid-group compounds can be calculated by those of individual analogues in a phosphoprotein phosphatase 2A assay.
Albano, C; Callegari, F; Ronzitti, G; Rossini, AM; Rossini, GP, 2009
)
0.35
" In animals dosed only with OA, epithelial hyperplasia of forestomach and slight focal subacute inflammation of its submucosa were noted."( Repeated oral co-exposure to yessotoxin and okadaic acid: a short term toxicity study in mice.
Ardizzone, M; Barreras, A; Beltramo, D; Dell'Ovo, V; Sosa, S; Tubaro, A; Vita, F; Yasumoto, T, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitorAny EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of phosphoprotein phosphatase (EC 3.1.3.16).
calcium ionophorenull
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
ketalAn acetal of formula R2C(OR)2 (R =/= H) derived from a ketone by replacement of the oxo group by two hydrocarbyloxy groups. The class name 'ketals', once abandoned by IUPAC, has been reinstated as a subclass of acetals.
polycyclic ether
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Serine/threonine protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)IC50 (µMol)0.09700.09700.09700.0970AID977608
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)0.45370.00053.49849.7600AID164500; AID164501; AID164504
Serine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)IC50 (µMol)1.96630.00000.15921.7800AID200563; AID200564; AID200565; AID200566; AID200567; AID200568; AID200569; AID200570; AID200571; AID200720; AID200723
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)IC50 (µMol)0.00700.00700.00700.0070AID164512
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B Gallus gallus (chicken)IC50 (µMol)0.00090.00010.41982.9000AID164506; AID164672; AID164674; AID200735
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (59)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
MAPK cascadeSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
blastocyst developmentSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
glycogen metabolic processSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein dephosphorylationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
spermatogenesisSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
neuron differentiationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
circadian regulation of gene expressionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
regulation of circadian rhythmSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
entrainment of circadian clock by photoperiodSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
regulation of nucleocytoplasmic transportSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cell divisionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
positive regulation of glial cell proliferationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
mitotic sister chromatid segregationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
regulation of protein phosphorylationSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
protein dephosphorylationSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
mesoderm developmentSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
response to lead ionSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of epithelial to mesenchymal transitionSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of hippo signalingSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
peptidyl-threonine dephosphorylationSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
regulation of growthSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
T cell homeostasisSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
regulation of cell differentiationSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
meiotic cell cycleSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
peptidyl-serine dephosphorylationSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of protein serine/threonine kinase activitySerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblySerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
regulation of microtubule bindingSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of microtubule bindingSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of glycolytic process through fructose-6-phosphateSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
regulation of G1/S transition of mitotic cell cycleSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
mitotic cell cycleSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
RNA bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
phosphoprotein phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein serine/threonine phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
lamin bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein phosphatase 1 bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
myosin phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein kinase bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein domain specific bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein-containing complex bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
metal ion bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
phosphoprotein phosphatase activitySerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
protein serine/threonine phosphatase activitySerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
protein tyrosine phosphatase activitySerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
protein bindingSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
myosin phosphatase activitySerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
metal ion bindingSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
protein heterodimerization activitySerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
tau protein bindingSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
GABA receptor bindingSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
kinetochoreSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nucleusSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nucleolusSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cytoplasmSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
mitochondrionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
mitochondrial outer membraneSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
microtubule organizing centerSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cytosolSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
focal adhesionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nuclear speckSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
midbodySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cleavage furrowSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
dendritic spineSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
presynapseSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
glutamatergic synapseSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein-containing complexSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
PTW/PP1 phosphatase complexSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nucleusSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cytoplasmSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
chromosome, centromeric regionSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
spindle poleSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
nucleusSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
mitochondrionSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
cytosolSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
plasma membraneSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
microtubule cytoskeletonSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
membraneSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
membrane raftSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
synapseSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
extracellular exosomeSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
protein phosphatase type 2A complexSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
protein serine/threonine phosphatase complexSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
FAR/SIN/STRIPAK complexSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
cytosolSerine/threonine-protein phosphatase 2A catalytic subunit alpha isoformHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (62)

Assay IDTitleYearJournalArticle
AID164504Observed inhibition activity against protein phosphatase 1 (PP1)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.
AID175140Duration of plateau(min) in estrogen-primed rat uterus at 20 uM in Ca+2-free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID665867Inhibition of PP2A using p-NPP as substrate pretreated for 1 hr by spectrophotometry2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
The structures of three metabolites of the algal hepatotoxin okadaic acid produced by oxidation with human cytochrome P450.
AID398384Cytotoxicity against african green monkey CV1 cells assessed as zone of diameter at 0.1 ug/ml1995Journal of natural products, May, Volume: 58, Issue:5
A new polyether acid from a cold water marine sponge, a Phakellia species.
AID200564Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type C127S by compound was evalutade2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID527294Blockade of okadaic acid-induced cytotoxicity in mouse P388 cells after 2 days by WST-8 assay in presence of Halichondria okadai recombinant OABP 2.12010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Binding of diarrheic shellfish poisoning toxins to okadaic acid binding proteins purified from the sponge Halichondria okadai.
AID164506Concentration required to inhibit the action of protein phosphatase 2A2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID200730Inhibitory activity against serine/threonine protein phosphatase 2 (PP2A)2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Self-association of okadaic acid upon complexation with potassium ion.
AID665868Drug metabolism in presence of human recombinant CYP3A4 by MS/MS analysis2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
The structures of three metabolites of the algal hepatotoxin okadaic acid produced by oxidation with human cytochrome P450.
AID200726Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type E252A:D253A by compound was evalutade; ND means not determined.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200728Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type E256R by compound was evalutade; ND means not determined.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID175142Duration of plateau(min) in estrogen-primed rat uterus at 20 uM in [Ca2+] free Na+free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID200571Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type Y272F by compound was evalutade2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID527292Displacement of [24-3H]OA from Halichondria okadai recombinant OABP 2.1 expressed in Escherichia coli BL21 (DE3) cells2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Binding of diarrheic shellfish poisoning toxins to okadaic acid binding proteins purified from the sponge Halichondria okadai.
AID179874Emax value in estrogen-primed rat uterus at 20 uM in Ca+2-free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID1490880Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Limaol: A Polyketide from the Benthic Marine Dinoflagellate Prorocentrum lima.
AID180019Emax value in estrogen-primed rat uterus at 20 uM in [Ca2+] free Na+free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID527296Blockade of mitomycin-induced cytotoxicity in mouse P388 cells after 2 days by WST-8 assay in presence of Halichondria okadai recombinant OABP 2.12010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Binding of diarrheic shellfish poisoning toxins to okadaic acid binding proteins purified from the sponge Halichondria okadai.
AID200892Exogenous inhibition concentration of Serine/threonine protein phosphatase 5 (PP5); ND means not determined.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID179875Emax value in estrogen-primed rat uterus at 20 uM in Ca+2-free K+free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID164500Inhibition activity against protein phosphatase 1 (PP1), activity taken from literature1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.
AID157188Inhibitory activity against PSPTase2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase.
AID200567Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type E275R by compound was evalutade2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID527293Displacement of [24-3H]OA from Halichondria okadai recombinant OABP 2.3 expressed in Escherichia coli BL21 (DE3) cells2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Binding of diarrheic shellfish poisoning toxins to okadaic acid binding proteins purified from the sponge Halichondria okadai.
AID398385Cytotoxicity against african green monkey CV1 cells assessed as zone of diameter at 0.01 ug/ml1995Journal of natural products, May, Volume: 58, Issue:5
A new polyether acid from a cold water marine sponge, a Phakellia species.
AID200749Exogenous inhibition concentration of Serine/threonine protein phosphatase 2C (PP2C); NI means no inhibition.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200720Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutants by natural toxins in wild type2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID164490Inhibitory concentration against Protein phosphatase 1(10 nM) isolated from rabbit muscle2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Importance of the C28-C38 hydrophobic domain of okadaic acid for potent inhibition of protein serine-threonine phosphatases 1 and 2A.
AID190796Time to peak tension(min) in estrogen-primed rat uterus at 20 uM in [Ca2+] free K+free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID164512Inhibitory concentration against Protein phosphatase 2A (25 nM) isolated from bovine myocardial tissue2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Importance of the C28-C38 hydrophobic domain of okadaic acid for potent inhibition of protein serine-threonine phosphatases 1 and 2A.
AID200742Exogenous inhibition concentration of Serine/threonine protein phosphatase 2B (PP2B)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200735Exogenous inhibition concentration of Serine/threonine protein phosphatase 2A (PP2A)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID174402Decrease in tone in estrogen-primed rat uterus at 20 uM in Ca+2-free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID200563Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type H248N by compound was evalutade2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID482868Neuroprotective activity in human SH-SY5Y cells assessed as protection against okadaic acid-induced cell death at 1 uM after 24 hrs by MTT assay2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
AID164672Inhibition activity against protein phosphatase 2A (PP2A), activity taken from literature1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.
AID164501Inhibitory concentration against Protein phosphatase 1 was determined2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID174403Decrease in tone in estrogen-primed rat uterus at 20 uM in [Ca2+] free K+free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID200751Exogenous inhibition concentration of Serine/threonine protein phosphatase 4 (PP4)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID1490882Cytotoxicity against mouse Neuro2a cells after 24 hrs by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Limaol: A Polyketide from the Benthic Marine Dinoflagellate Prorocentrum lima.
AID200727Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type E252A:D253A:E256R by compound was evalutade; ND means not determined.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID164674Observed inhibition activity against protein phosphatase 2A (PP2A)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.
AID527295Blockade of okadaic acid-induced cytotoxicity in mouse P388 cells after 2 days by WST-8 assay in presence of Halichondria okadai recombinant OABP 2.32010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Binding of diarrheic shellfish poisoning toxins to okadaic acid binding proteins purified from the sponge Halichondria okadai.
AID200565Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type D208A by compound was evalutade2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID190797Time to peak tension(min) in estrogen-primed rat uterus at 20 uM in [Ca2+] free Na+free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID174404Decrease in tone in estrogen-primed rat uterus at 20 uM in [Ca2+] free Na+free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID200561Exogenous inhibition of Serine/threonine protein phosphatase 1 (PP1)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200568Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type N124D by compound was evalutade2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID398383Cytotoxicity against mouse L1210 cells1995Journal of natural products, May, Volume: 58, Issue:5
A new polyether acid from a cold water marine sponge, a Phakellia species.
AID665872Inhibition of protein phosphatase 12012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
The structures of three metabolites of the algal hepatotoxin okadaic acid produced by oxidation with human cytochrome P450.
AID200725Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type D95A by compound was evalutade; ND means not determined.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200566Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type D220V by compound was evalutade2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200569Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type R221S by compound was evalutade2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200570Inhibition of Serine/threonine protein phosphatase 1 (PP1) mutant type R96A by compound was evalutade2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID175141Duration of plateau(min) in estrogen-primed rat uterus at 20 uM in [Ca2+] free K+free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID190795Time to peak tension(min) in estrogen-primed rat uterus at 20 uM in Ca+2-free solution1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Complexation of okadaic acid: a preliminary study.
AID1490881Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Limaol: A Polyketide from the Benthic Marine Dinoflagellate Prorocentrum lima.
AID82568Inhibitory concentration against casein dephosphorylation (casein is a substrate of PP-2A) by a HIT cell extract2000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Michael adducts of ascorbic acid as inhibitors of protein phosphatase 2A and inducers of apoptosis.
AID200723Inhibitory activity against serine/threonine protein phosphatase 1(PP1)2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Self-association of okadaic acid upon complexation with potassium ion.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2004The Journal of biological chemistry, Oct-08, Volume: 279, Issue:41
Crystal structure and mutagenesis of a protein phosphatase-1:calcineurin hybrid elucidate the role of the beta12-beta13 loop in inhibitor binding.
AID1811Experimentally measured binding affinity data derived from PDB2004The Journal of biological chemistry, Oct-08, Volume: 279, Issue:41
Crystal structure and mutagenesis of a protein phosphatase-1:calcineurin hybrid elucidate the role of the beta12-beta13 loop in inhibitor binding.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,790)

TimeframeStudies, This Drug (%)All Drugs %
pre-199053 (1.40)18.7374
1990's1824 (48.13)18.2507
2000's1178 (31.08)29.6817
2010's592 (15.62)24.3611
2020's143 (3.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.42 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index62.74 (26.88)
Search Engine Supply Index2.05 (0.95)

This Compound (43.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.05%)5.53%
Trials0 (0.00%)5.53%
Reviews88 (2.28%)6.00%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other3,775 (97.67%)84.16%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]